Advantages |
• Derived from human pluripotent stem cells (hPSCs) allowing models of disease states and genetic variability |
• Engineered microchips with primary human kidney cells to mimic kidney functions |
• Contains more than 1 cell type allowing simultaneous toxicity screenings of multiple cell types |
• Recapitulate fluid shear stress and mechanical strain |
• Recapitulates interactions between different cell types present in the system |
• Media to cell ratios approximate physiological values |
• Cells maintain proper gene expression and phenotypes longer than traditional 2D cultures, allowing for longer treatments and studies |
• Under consideration by pharmaceutical industry and regulatory agencies |
• Ability to respond to stress by expressing and/or releasing injury markers in specific cell types |
|
• Can be automated allowing for higher-throughput screening |
|
Disadvantages |
• Lack of vascularization |
• Inconsistent reproducibility due to variability from both donors and suppliers |
• Lacks physiologically relevant components such as fluid flow |
• Lack of standardized kidney chip format allows more variability |
• Limited ability to grow and mature |
• The majority of reported kidney MPS models are limited to PTECs |
• Differences in hPSC sources and differentiation protocols could lead to batch-to-batch variability, affecting experimental reproducibility |
• High cost of a single MPS platform |
|
• Potential adsorption of test agents by PDMS in many systems |
|
• In vitro-in vivo translation requires optimization in multi MPS scaling |
Culture time |
• Slower (weeks to months) to establish due to lengthy hPSC induction |
• Faster (days to weeks) |